TC-G 1005 is primarily used as a selective agonist for the glucagon-like peptide-1 (GLP-1) receptor in research settings. It is employed to study glucose homeostasis, insulin secretion, and beta-cell function in models of diabetes and metabolic disorders. Due to its stability and receptor specificity, it serves as a valuable tool compound in preclinical studies aimed at understanding the signaling pathways and therapeutic potential of GLP-1 activation. Its application supports the development of new antidiabetic agents and helps evaluate the physiological effects of sustained GLP-1 receptor stimulation without the need for peptide-based drugs.